JP2009532504A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532504A5
JP2009532504A5 JP2009504471A JP2009504471A JP2009532504A5 JP 2009532504 A5 JP2009532504 A5 JP 2009532504A5 JP 2009504471 A JP2009504471 A JP 2009504471A JP 2009504471 A JP2009504471 A JP 2009504471A JP 2009532504 A5 JP2009532504 A5 JP 2009532504A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
substituted
compound according
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009504471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/066018 external-priority patent/WO2007118130A2/en
Publication of JP2009532504A publication Critical patent/JP2009532504A/ja
Publication of JP2009532504A5 publication Critical patent/JP2009532504A5/ja
Pending legal-status Critical Current

Links

JP2009504471A 2006-04-06 2007-04-05 抗菌薬 Pending JP2009532504A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74434806P 2006-04-06 2006-04-06
PCT/US2007/066018 WO2007118130A2 (en) 2006-04-06 2007-04-05 Antibacterial agents

Publications (2)

Publication Number Publication Date
JP2009532504A JP2009532504A (ja) 2009-09-10
JP2009532504A5 true JP2009532504A5 (enExample) 2010-05-27

Family

ID=38581812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504471A Pending JP2009532504A (ja) 2006-04-06 2007-04-05 抗菌薬

Country Status (4)

Country Link
US (1) US7709496B2 (enExample)
EP (1) EP2007377A4 (enExample)
JP (1) JP2009532504A (enExample)
WO (1) WO2007118130A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
PT2137196E (pt) * 2007-04-20 2010-12-16 Glaxo Group Ltd Compostos tricíclicos contendo azoto como agentes antibacterianos
GB0800367D0 (en) * 2008-01-09 2008-02-20 Glaxo Group Ltd Compounds
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
JP2012505866A (ja) 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
US8318940B2 (en) 2009-01-15 2012-11-27 Glaxo Group Limited Naphthyridin-2 (1 H)-one compounds useful as antibacterials
JP5768348B2 (ja) * 2009-09-17 2015-08-26 大日本印刷株式会社 熱塩基発生剤、高分子前駆体組成物、当該組成物を用いた物品
TW201309689A (zh) 2011-02-07 2013-03-01 Daiichi Sankyo Co Ltd 含胺基之吡咯啶酮衍生物
IN2014CN04126A (enExample) 2011-11-08 2015-07-10 Actelion Pharmaceuticals Ltd
WO2014024056A1 (en) 2012-08-06 2014-02-13 Daiichi Sankyo Company, Limited Pyrrolidine derivatives with antibacterial properties
CN103864588B (zh) * 2014-03-25 2015-09-09 河北工业大学 一种2,3-二甲氧基苯甲醛的制备方法
AR101674A1 (es) 2014-08-22 2017-01-04 Glaxosmithkline Ip Dev Ltd Uso de un compuesto tricíclico que contiene nitrógeno
WO2020169593A1 (en) 2019-02-19 2020-08-27 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
ZA931343B (en) 1992-03-06 1993-09-24 Akzo Nv 1,4-dioxino(2,3-b)pyridine derivatives.
US6077857A (en) 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
AU2717899A (en) 1998-01-26 1999-08-09 Smithkline Beecham Plc Quinoline derivatives as antibacterials
WO1999065867A1 (en) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
AU1324300A (en) 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
JP2002535323A (ja) 1999-01-20 2002-10-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー プロテインキナーゼ阻害剤としてのピペリジニルキノリン
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
KR20020087041A (ko) 1999-07-28 2002-11-21 아벤티스 파마슈티칼스 프로덕츠 인크. 치환된 옥소아자헤테로사이클릴 화합물
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
ATE260272T1 (de) 2000-03-17 2004-03-15 Bristol Myers Squibb Pharma Co Beta-aminsäure-derivate zur verwendung als matrix-metalloproteasen- und tna-alpha-inhibitoren
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
EP1719770A3 (en) 2000-09-21 2008-03-05 Smithkline Beecham Plc Quinoline derivatives as antibacterials
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
AU2002219175A1 (en) 2000-12-21 2002-07-01 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003048081A2 (en) * 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR040335A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
AU2003303956A1 (en) 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
AR042486A1 (es) * 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス, インコーポレーテッド 置換4−アミノ−1−ベンジルピペリジン化合物
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ グループ リミテッド 抗細菌剤
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
EP1784410A4 (en) 2004-08-09 2009-07-15 Glaxo Group Ltd ANTIBACTERIAL AGENTS

Similar Documents

Publication Publication Date Title
JP2008506695A5 (enExample)
JP2008507543A5 (enExample)
SE0402735D0 (sv) Novel compounds
CY1111032T1 (el) Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων
GEP20125405B (en) Amino-heterocyclic compounds
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
JP2005525324A5 (enExample)
JP2008505920A5 (enExample)
JP2008505926A5 (enExample)
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
JP2008502689A5 (enExample)
MY140868A (en) Amide derivatives
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
DE602004009905D1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
CY1107401T1 (el) Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson
JP2008508359A5 (enExample)
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
TW200640879A (en) Amide derivatives
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
PE20071090A1 (es) 5-pirazolpiperidinas-(sustituidas)
AR035945A1 (es) Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)